Modalis Therapeutics Corporation

As of June 30, 2026, Modalis Therapeutics Corporation carries a market capitalization of 3.21B, placing it among publicly traded companies globally. Its enterprise value stands at 196.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Modalis Therapeutics Corporation's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Modalis Therapeutics Corporation has 97.33M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Modalis Therapeutics Corporation maintains a current ratio of 4.68, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, Modalis Therapeutics Corporation's stock has declined approximately 65.00% over the past 52 weeks. The 50-day moving average sits at 32.52, while the 200-day moving average is 46.09.

These figures are as of June 30, 2026. Total book value stands at 2.47B, with working capital of 2.42B providing operational flexibility.